
Dr. Jerome Kim, Director General of IVI, and Seoul National University President Prof. Honglim Ryu exchange an MOU during a signing ceremony at SNU on June 20, 2023. Credit: IVI
June 21, 2023, SEOUL, Republic of Korea – The International Vaccine Institute (IVI) and Seoul National University signed an agreement to expand collaboration in research.
IVI is the only international organization dedicated to the development and delivery of new vaccines to protect people in low-income countries from infectious diseases, and the first international organization to be headquartered in the Republic of Korea. The institute has been based in Seoul National University Research Park since its establishment in 1997.
Under the agreement, the two organizations will promote mutual cooperation in vaccine research and development, including the exchange of academic information and data for the discovery of new vaccines, and conduct of joint symposia and academic events and joint research and collaborative projects.
SNU has been engaging in research and academic exchange collaborations (with various organizations) that are necessary to address vaccine inequity and prevent infectious diseases in the international community based on its excellent education and research capacity.
“Building on the collaborative relationship between SNU and IVI that has continued since IVI’s inception, SNU will spare no effort to support research and education to prevent infectious diseases and improve public health and safety, and we will continue to expand SNU’s responsibilities beyond Korea to the world and humanity,” SNU President Honglim Ryu said.
Dr. Jerome Kim, Director General of IVI, said, “IVI has had the privilege of having its headquarters on the campus of Seoul National University, one of the most prestigious academic institutions in the world. This agreement will open a new horizon to further expand our partnerships and collaborations in vaccines and related fields to accelerate vaccine science and innovation and contribute to global health.”
The signing ceremony at SNU was attended by President Honglim Ryu, Vice President for Research Jae-young Kim, Dean of Research Affairs Byung-cheol Kang from SNU; and Director General Dr. Jerome Kim, Deputy Director General of Government and Public Relations Dr. Kyung-taik Han and Deputy Director General of Science Dr. Manki Song from IVI.
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.